Juyong B Kim, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A102168 · Current
Licensed to practise in California · since 2007 · expires 2027-10-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,115
Medicare paid this office $47,115 for 632 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 69 | $12,682 | $181 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 18 | $8,929 | $470 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 431 | $3,394 | $7 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 13 | $3,176 | $244 |
| Biopsy of heart muscle | 11 | $2,696 | $193 |
See all 11 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 69 | $12,682 | $181 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 18 | $8,929 | $470 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 431 | $3,394 | $7 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 13 | $3,176 | $244 |
| Biopsy of heart muscle | 11 | $2,696 | $193 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 20 | $1,655 | $79 |
| Return visit (30+ min) | 12 | $1,227 | $88 |
| Insertion of tube in right heart chambers for measurement | 11 | $1,153 | $105 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 96 | $1,030 | $10 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 41 | $897 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $138 | $13 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 17 | More than 43% of doctors who do this |
Who their Medicare patients are
632 Original Medicare patients in 2024. Average age 74 · Under 65 10% · 85 and older 17% · Women 51% · Also on Medicaid 36% · Health risk score 2.35. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 55% · Chronic kidney disease 48% · Diabetes 45% · Heart failure 45% · Atrial fibrillation 45% · Depression 25% · Cancer 24% · COPD 20% · Dementia 16% · Stroke 16%.
The office billed $699,944, Medicare allowed $59,469 and paid $47,115; for 855 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 632 | 855 | 74 | 2.35 | $699,944 | $47,115 |
| 2023 | 376 | 618 | 73 | 2.48 | $661,009 | $49,675 |
| 2022 | 158 | 351 | 72 | 2.15 | $534,491 | $42,855 |
| 2021 | 156 | 328 | 70 | 2.58 | $504,407 | $44,821 |
| 2020 | 77 | 158 | 70 | 2.45 | $247,419 | $20,558 |
| 2019 | 66 | 154 | 69 | 3.09 | $184,779 | $19,682 |
| 2018 | 112 | 247 | 68 | 2.89 | $273,776 | $33,447 |
| 2017 | 150 | 398 | 69 | 2.81 | $385,754 | $50,803 |
| 2016 | 67 | 99 | 71 | 2.10 | $128,943 | $19,793 |
| 2015 | 40 | 52 | 74 | 2.81 | $79,353 | $11,521 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 71 | $12,518 | $176 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 19 | $9,978 | $454 |
| Biopsy of heart muscle | 19 | $3,955 | $188 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $2,936 | $267 |
| New patient visit (60+ min) | 15 | $2,338 | $156 |
| Insertion of tube in right heart chambers for measurement | 20 | $2,269 | $108 |
| Return visit (30+ min) | 22 | $2,076 | $74 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 22 | $1,789 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 186 | $1,593 | $7 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 84 | $408 | $5 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $407 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $264 | $11 |
2022: 8 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 72 | $13,338 | $185 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 16 | $8,868 | $467 |
| Biopsy of heart muscle | 12 | $2,709 | $193 |
| New patient visit (60+ min) | 16 | $2,362 | $148 |
| Return visit (30+ min) | 22 | $2,134 | $85 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 19 | $1,564 | $82 |
| Insertion of tube in right heart chambers for measurement | 14 | $1,554 | $111 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 104 | $507 | $5 |
2021: 9 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 63 | $12,017 | $191 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $7,221 | $481 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 16 | $4,417 | $276 |
| Biopsy of heart muscle | 17 | $4,032 | $192 |
| New patient visit (60+ min) | 19 | $3,309 | $174 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 20 | $1,600 | $80 |
| Return visit (30+ min) | 13 | $1,307 | $87 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 65 | $746 | $11 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 22 | $107 | $5 |
2020: 4 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 37 | $7,362 | $199 |
| Biopsy of heart muscle | 11 | $2,436 | $203 |
| Short return visit (20+ min) | 13 | $739 | $39 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 43 | $489 | $11 |
2019: 3 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 29 | $5,712 | $190 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 12 | $1,012 | $84 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 42 | $466 | $11 |
2018: 7 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 47 | $8,580 | $179 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,827 | $455 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 15 | $3,812 | $254 |
| Biopsy of heart muscle | 16 | $3,024 | $159 |
| New patient visit (60+ min) | 11 | $1,463 | $133 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,121 | $80 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 68 | $738 | $11 |
2017: 8 services
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 83 | $15,160 | $180 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 19 | $10,132 | $482 |
| Biopsy of heart muscle | 24 | $6,061 | $168 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $2,846 | $259 |
| New patient visit (60+ min) | 13 | $1,928 | $148 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 20 | $1,653 | $83 |
| Insertion of tube in right heart chambers for measurement | 19 | $1,642 | $82 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 125 | $1,462 | $11 |
2016: 1 service
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 32 | $6,695 | $209 |
2015: 1 service
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 11 | $2,096 | $191 |
Medicaid work
$3,711 in 2024
Medicaid paid $3,711 for 337 billed services this clinician did in 2024, up to 177 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 325 | $3,400 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 12 | $311 |
| 2024 | 337 | 2 | 177 | $3,711 |
| 2023 | 217 | 1 | 98 | $2,039 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 217 | $2,039 |
Drugs they prescribed that Part D paid
$23,313
Pharmacies billed $23,313 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 234) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
221 generic and 13 brand-name prescriptions · $23,313 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rosuvastatin | 23 | $948 | $41 |
| Atorvastatin | 37 | $519 | $14 |
| Clopidogrel | 29 | $473 | $16 |
| Isosorbide Mononitrate Er | 13 | $292 | $22 |
| Carvedilol | 11 | $289 | $26 |
See all 8 drugs
| Rosuvastatin | 23 | $948 | $41 |
| Atorvastatin | 37 | $519 | $14 |
| Clopidogrel | 29 | $473 | $16 |
| Isosorbide Mononitrate Er | 13 | $292 | $22 |
| Carvedilol | 11 | $289 | $26 |
| Metoprolol | 28 | $275 | $10 |
| Amlodipine Besylate | 17 | $44 | $3 |
| Metoprolol | 11 | $21 | $2 |
Year by year
| 2024 | 234 | 45 | 0% (0) | 6% | $23,313 |
| 2023 | 251 | 43 | 0% (0) | 6% | $30,151 |
| 2022 | 254 | 40 | 0% (0) | 9% | $38,653 |
| 2021 | 199 | 34 | None | 13% | $28,914 |
| 2020 | 118 | 15 | 0% (0) | 11% | $13,506 |
| 2019 | 83 | 16 | 0% (0) | 13% | $5,691 |
| 2018 | 51 | 14 | None | 22% | $5,283 |
| 2017 | 25 | None | None | None | $2,413 |
| 2014 | 17 | None | None | 0% | $660 |
| 2013 | 15 | None | None | 0% | $475 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Eliquis | 12 | $18,457 | $1,538 |
| Rosuvastatin | 19 | $1,486 | $78 |
| Isosorbide Mononitrate Er | 20 | $1,009 | $50 |
| Atorvastatin | 34 | $636 | $19 |
| Metoprolol | 25 | $419 | $17 |
| Clopidogrel | 15 | $406 | $27 |
| Carvedilol | 17 | $352 | $21 |
| Spironolactone | 11 | $208 | $19 |
2022: 10 drugs
| Eliquis | 14 | $23,591 | $1,685 |
| Atorvastatin | 43 | $729 | $17 |
| Rosuvastatin | 13 | $630 | $48 |
| Isosorbide Mononitrate Er | 17 | $487 | $29 |
| Metoprolol | 17 | $324 | $19 |
| Clopidogrel | 11 | $298 | $27 |
| Carvedilol | 17 | $229 | $13 |
| Spironolactone | 11 | $183 | $17 |
| Losartan | 13 | $106 | $8 |
| Metoprolol | 12 | $101 | $8 |
2021: 5 drugs
| Carvedilol | 25 | $457 | $18 |
| Atorvastatin | 30 | $388 | $13 |
| Clopidogrel | 11 | $201 | $18 |
| Amlodipine Besylate | 20 | $192 | $10 |
| Losartan | 11 | $123 | $11 |
2020: 3 drugs
| Carvedilol | 25 | $398 | $16 |
| Atorvastatin | 13 | $195 | $15 |
| Amlodipine Besylate | 15 | $73 | $5 |
2019: 2 drugs
| Carvedilol | 14 | $276 | $20 |
| Atorvastatin | 11 | $256 | $23 |
2018: 2 drugs
| Atorvastatin | 11 | $222 | $20 |
| Clopidogrel | 13 | $179 | $14 |
2014: 1 drug
| Clopidogrel | 11 | $497 | $45 |
Money from drug and device companies
$1,536 in 2023
A payment is not proof that care is biased.
| Janssen Research & Development | None | $1,370 | 10 payments
|
| Boston Scientific | None | $165 | 1 payment
|
See all 11 published payments
| Janssen Research & Development | Travel · 2023-09-14 | None | $44 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $150 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $40 |
| Janssen Research & Development | Travel · 2023-09-14 | None | $249 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $20 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $20 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $60 |
| Janssen Research & Development | Meals · 2023-09-14 | None | $20 |
| Janssen Research & Development | Travel · 2023-08-24 | None | $359 |
| Janssen Research & Development | Travel · 2023-08-24 | None | $408 |
| Boston Scientific | Meals · 2023-05-02 | None | $165 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Study of Milvexian in Participants After A Recent Acute Coronary Syndrome (Librexia-Acs) · 2025 | Their institution | $101,537 |
| Janssen Research & Development, LLC · 2024 | Their institution | $68,624 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1043462146
- Licence
- CA A102168California A102168: Current · expires 2027-10-31
- Trained
- New York University School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-10-21
- NPI last updated
- 2024-04-22
- NPI record certified
- 2024-04-22
This is when the NPI record was last certified, not a medical board exam.